Enzymotec (ENZY) Given News Sentiment Rating of 0.12

News stories about Enzymotec (NASDAQ:ENZY) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Enzymotec earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.0970384744145 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Enzymotec (NASDAQ:ENZY) traded up $0.02 on Monday, hitting $11.82. The stock had a trading volume of 62,000 shares, compared to its average volume of 66,608. Enzymotec has a 52 week low of $5.80 and a 52 week high of $12.35.

Several equities analysts recently issued reports on ENZY shares. Wells Fargo & Company raised their price objective on Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a research note on Monday, October 30th. Jefferies Group reaffirmed a “hold” rating and issued a $11.50 target price on shares of Enzymotec in a research report on Thursday, October 19th. ValuEngine raised Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Finally, Zacks Investment Research raised Enzymotec from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Four analysts have rated the stock with a hold rating, The stock has an average rating of “Hold” and a consensus target price of $11.75.

COPYRIGHT VIOLATION WARNING: “Enzymotec (ENZY) Given News Sentiment Rating of 0.12” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/12/04/enzymotec-enzy-given-news-sentiment-rating-of-0-12.html.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Insider Buying and Selling by Quarter for Enzymotec (NASDAQ:ENZY)

What are top analysts saying about Enzymotec Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enzymotec Ltd. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit